Understand the source comparison
GLOW Stack Administration: Injection vs Delivery Methods
Subcutaneous injection (abdomen) 95–100% 10–15 minutes 90–120 minutes (MOD GRF, GHRP-2); 2–3 hours (Ipamorelin) Optimal for GLOW stack Standard research method. Allows precise timing control and site rotation to prevent lipohypertrophy Intramuscular injection
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Subcutaneous injection (abdomen)
- 95–100%
- 10–15 minutes
- 90–120 minutes (MOD GRF, GHRP-2); 2–3 hours (Ipamorelin)
- Optimal for GLOW stack
- Standard research method. Allows precise timing control and site rotation to prevent lipohypertrophy
- Intramuscular injection
- 5–10 minutes
- 60–90 minutes
- Not recommended
- Faster onset but shorter duration. Disrupts the GLOW stack's designed timing sequence
- Nasal spray (intranasal)
- 30–50%
- 15–20 minutes
- Not compatible
- Low bioavailability and high inter-subject variability. Cannot achieve reliable plasma concentrations for stack synergy
- Oral capsule
- <5%
- N/A
- Not viable
- Peptides are degraded by gastric acid and proteolytic enzymes. No measurable plasma levels achieved
- The table above shows why subcutaneous injection remains the only viable delivery method for GLOW stack administration in research. Nasal sprays and oral forms. Occasionally marketed for peptides like Semax or Selank in nootropic contexts. Cannot achieve the plasma concentration consistency required for multi-peptide synergy. Subcutaneous administration into adipose tissue allows for slow, steady absorption with predictable pharmacokinetics.